0.6125

3.22% 0.007

Prophase Labs Inc (PRPH)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$0.6055

Offen:

$0.6

24-Stunden-Volumen:

12,043

Relative Volume:

0.05

Marktkapitalisierung:

$14.46M

Einnahmen:

$62.71M

Nettoeinkommen (Verlust:

$-10.48M

KGV:

-0.9722

EPS:

-0.63

Netto-Cashflow:

$-13.77M

1W Leistung:

+6.11%

1M Leistung:

-3.99%

6M Leistung:

-80.59%

1J Leistung:

-87.24%

1-Tages-Spanne:

$0.60

$0.6129

1-Wochen-Bereich:

$0.57

$0.67

52-Wochen-Spanne:

$0.56

$7.48

Prophase Labs Inc Stock (PRPH) Company Profile

Firmenname

Prophase Labs Inc

Sektor

Healthcare (1191)

Branche

Diagnostics & Research (58)

Telefon

(215) 345-0919

Adresse

711 STEWART AVE, SUITE 200, NEW YORK, PA

Mitarbeiter

113

Twitter

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

PRPH's Discussions on Twitter

Vergleichen Sie PRPH mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
PRPH Prophase Labs Inc	0.6125	14.46M	62.71M	-10.48M	-13.77M	-0.63
TMO Thermo Fisher Scientific Inc	557.45	213.05B	42.37B	6.14B	7.78B	15.95
DHR Danaher Corp	239.82	171.63B	23.74B	3.89B	4.98B	5.24
A Agilent Technologies Inc	145.66	40.96B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	197.21	35.93B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	428.52	34.28B	3.84B	866.24M	792.60M	10.37

Prophase Labs Inc Stock (PRPH) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2021-12-20	Eingeleitet	H.C. Wainwright	Buy
2021-10-13	Herabstufung	Dawson James	Buy → Neutral
2021-01-20	Eingeleitet	Dawson James	Buy

Prophase Labs Inc Aktie (PRPH) Neueste Nachrichten

Jan 12, 2025

PRPH (ProPhase Labs) Debt-to-EBITDA : -1.36 (As of Sep. 2024) - GuruFocus.com

Jan 12, 2025

Jan 08, 2025

ProPhase Labs stock hits 52-week low at $0.61 amid sharp decline - Investing.com Canada

Jan 08, 2025

Dec 29, 2024

ProPhase Labs Receives Notice from NASDAQ Regarding Minimum Bid Price Requirement On December 26, 2024, ProPhase Labs, Inc. (NASDAQ: PRPH) received a letter from the Listing Qualifications Staff of The Nasdaq Stock Market LLC, indicating that t - Defense World

Dec 29, 2024

Dec 28, 2024

ProPhase Labs faces potential Nasdaq delisting over share price By Investing.com - Investing.com Nigeria

Dec 28, 2024

ProPhase Labs faces potential Nasdaq delisting over share price - Investing.com

Dec 28, 2024

Dec 22, 2024

HighTower Advisors LLC Boosts Stock Position in ProPhase Labs, Inc. (NASDAQ:PRPH) - Defense World

Dec 22, 2024

Dec 20, 2024

ProPhase Labs stock hits 52-week low at $0.64 amid sharp decline - Investing.com Australia

Dec 20, 2024

ProPhase Labs stock hits 52-week low at $0.64 amid sharp decline By Investing.com - Investing.com South Africa

Dec 20, 2024

Dec 12, 2024

ProPhase Labs stock hits 52-week low at $0.66 amid sharp decline By Investing.com - Investing.com South Africa

Dec 12, 2024

Dec 11, 2024

ProPhase Labs stock hits 52-week low at $0.66 amid sharp decline - Investing.com

Dec 11, 2024

ProPhase Labs secures private equity backing, nears lozenge deal, and plans cost-cutting measures - MSN

Dec 11, 2024

ProPhase Labs Secures Global Private Equity Backing, Nears Major Lozenge Deal, Adds Seasoned Industry Expert, and Plans Significant Cost-Cutting Measures - The Manila Times

Dec 11, 2024

ProPhase Labs Secures Global Private Equity Backing, Nears - GlobeNewswire

Dec 11, 2024

ProPhase Labs Secures Game-Changing Financing Deal, Eyes Major Asian Market Expansion - StockTitan

Dec 11, 2024

Dec 05, 2024

PRPH (ProPhase Labs) 5-Day RSI : 18.93 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

Nov 27, 2024

ProPhase Labs Launches Genetic Testing Subsidiary with Advanced Technology - Precedence Research

Nov 27, 2024

Nov 26, 2024